hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate effect.
hVIVO appoints Nominated Adviser and Joint Broker
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
hVIVO plc (LON:HVO), a leader in human challenge clinical trials, will announce its 2024 results on April 10, 2025, with an analyst briefing to follow.
hVIVO plc, a leader in human challenge clinical trials, has acquired Cryo-Store Limited to enhance its biobank and laboratory services with advanced storage solutions.
hVIVO plc secures a £2 million contract post-successful hMPV trial, advancing critical human challenge studies for future vaccine development.
hVIVO plc, a leader in human challenge clinical trials, reports successful Phase 2a results for Shionogi's RSV antiviral, S-337395, showing significant efficacy.
hVIVO plc partners with Inhalon Biopharma to test IN-002, an inhaled antiviral for RSV, in a Phase 2a trial using their RSV Human Challenge Model.
hVIVO expands its clinical footprint by acquiring CRS, a German CRO, adding Phase I & II trial capabilities in Europe, enhancing strategic growth for 2025-2026.
